459 results on '"Iwasaki, Akiko"'
Search Results
2. Factors Associated With Long COVID: Insights From Two Nationwide Surveys
3. Supplementary Data S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
4. Supplementary Table S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
5. Supplementary Figure S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
6. Supplementary Data S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
7. Supplementary Figure S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
8. Data from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
9. Supplementary Table S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
10. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
11. Long COVID Characteristics and Experience: A Descriptive Study from the Yale LISTEN Research Cohort
12. Sex differences in symptomatology and immune profiles of Long COVID
13. Compartmentalized ocular lymphatic system mediates eye–brain immunity
14. Post-Vaccination Syndrome: A Descriptive Analysis of Reported Symptoms and Patient Experiences After Covid-19 Immunization
15. Table S7 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
16. Table S2 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
17. Fig S4 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
18. Fig S7 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
19. Fig S4 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
20. Data from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
21. Table S3 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
22. Table S10 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
23. Figure S1 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
24. FIGURE 1 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
25. Fig S6 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
26. Fig S5 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
27. Table S3 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
28. Table S4 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
29. Table S6 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
30. Figure S2 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
31. Table S2 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
32. Supplementary Methods from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
33. Figure S2 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
34. Table S1 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
35. Table S9 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
36. Figure S1 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
37. Fig S9 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
38. FIGURE 2 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
39. Supplementary Methods from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
40. Fig S7 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
41. Fig S10 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
42. Fig S3 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
43. Table S7 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
44. Fig S11 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
45. Fig S9 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
46. Fig S6 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
47. Table S5 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
48. FIGURE 3 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
49. Fig S8 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
50. Fig S5 from Cancer Relevance of Circulating Antibodies Against LINE-1 Antigens in Humans
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.